<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.0 20040830//EN" "journalpublishing.dtd"><?covid-19-tdm?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="2.0" xml:lang="en" article-type="reviewer-report"><front><journal-meta><journal-id journal-id-type="nlm-ta">JMIRx Med</journal-id><journal-id journal-id-type="publisher-id">xmed</journal-id><journal-id journal-id-type="index">34</journal-id><journal-title>JMIRx Med</journal-title><abbrev-journal-title>JMIRx Med</abbrev-journal-title><issn pub-type="epub">2563-6316</issn></journal-meta><article-meta><article-id pub-id-type="publisher-id">50501</article-id><article-id pub-id-type="doi">10.2196/50501</article-id><title-group><article-title>Peer Review of &#x201C;Seroprevalence of SARS-CoV-2 in Niger State: Pilot Cross-Sectional Study&#x201D;</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Anonymous</surname><given-names>&#x00AD;</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Meinert</surname><given-names>Edward</given-names></name></contrib></contrib-group><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>17</day><month>10</month><year>2023</year></pub-date><volume>4</volume><elocation-id>e50501</elocation-id><history><date date-type="received"><day>03</day><month>07</month><year>2023</year></date><date date-type="accepted"><day>03</day><month>07</month><year>2023</year></date></history><copyright-statement>&#x00A9; Anonymous. Originally published in JMIRx Med (<ext-link ext-link-type="uri" xlink:href="https://med.jmirx.org">https://med.jmirx.org</ext-link>), 17.10.2023. </copyright-statement><copyright-year>2023</copyright-year><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIRx Med, is properly cited. The complete bibliographic information, a link to the original publication on <ext-link ext-link-type="uri" xlink:href="https://med.jmirx.org/">https://med.jmirx.org/</ext-link>, as well as this copyright and license information must be included.</p></license><self-uri xlink:type="simple" xlink:href="https://xmed.jmir.org/2023/1/e50501"/><related-article related-article-type="companion" ext-link-type="doi" xlink:href="10.1101/2020.08.04.20168112" xlink:title="Preprint (medRxiv)" xlink:type="simple">https://www.medrxiv.org/content/10.1101/2020.08.04.20168112v1</related-article><related-article related-article-type="companion" ext-link-type="doi" xlink:href="10.2196/50515" xlink:title="Authors' Response to Peer-Review Reports" xlink:type="simple">https://med.jmirx.org/2023/1/e50515</related-article><related-article related-article-type="companion" ext-link-type="doi" xlink:href="10.2196/29587" xlink:title="Published Article" xlink:type="simple">https://med.jmirx.org/2023/1/e29587</related-article><kwd-group><kwd>COVID-19</kwd><kwd>pandemic</kwd><kwd>SARS-CoV-2</kwd><kwd>seroprevalence</kwd><kwd>serology</kwd><kwd>epidemiology</kwd><kwd>Niger State</kwd><kwd>Nigeria</kwd><kwd>COVID-19 testing</kwd><kwd>social distancing</kwd></kwd-group></article-meta></front><body><sec id="s1"><title/><p><italic>This is a peer-review report submitted for the paper &#x201C;Seroprevalence of SARS-CoV-2 in Niger State: Pilot Cross-Sectional Study.&#x201D;</italic></p></sec><sec id="s2"><title>Review Round 1</title><sec id="s1-1"><title>General Comments</title><p>This paper, &#x201C;Seroprevalence of COVID-19 in Niger State: A Pilot Cross-Sectional Study&#x201D; by Majiya et al [<xref ref-type="bibr" rid="ref1">1</xref>], is valuable and worthy of publication. The paper describes the seroprevalence of COVID-19 in Niger State. The COVID-19 asymptomatic rate in the state was 46.81%. The study also observed that the chances of infection are almost the same for both urban and rural dwellers. Of great interest is the finding that health care workers and those who had contact with persons who traveled out of Nigeria in the last 6 months are twice as likely to be at risk of being infected with the virus. The paper is relevant and contributes to the knowledge of the epidemiology of the virus. However, one primary concern is that the information about the virus from which inferences were made in this paper seems outdated. There is a need for an update. Also, the work appears to be underpowered in terms of sample size.</p></sec><sec id="s1-2"><title>Specific Comments</title><list list-type="order"><list-item><p>The abstract is unusually extended; consider summarizing it, especially the results aspect.</p></list-item><list-item><p>There is a need for editing and restructuring some sentences.</p></list-item><list-item><p>Some long paragraphs have the same references; consider using other references as well.</p></list-item><list-item><p>Give a reference or definition for your sampling technique and probably describe how you achieved your sample size.</p></list-item><list-item><p>Avoid repeating the methodology in the Discussion session.</p></list-item><list-item><p>Add references to back up your inferences.</p></list-item><list-item><p>The authors should make inferences in light of observation and the literature; asymptomatic cases seem to foster community transmission. More so, isolation, quarantine, and lockdown, if need be, are some public health measures to halt transmission. I would instead advise that the authors make recommendations based on the data generated from the study.</p></list-item></list></sec></sec><sec id="s3"><title>Review Round 2</title><sec id="s2-1"><title>General Comments</title><p>This paper, &#x201C;Seroprevalence of COVID-19 in Niger State: A Pilot Cross-Sectional Study,&#x201D; is a credible addition to the body of knowledge about COVID-19 in Niger State and Nigeria as a whole. The Abstract has been refined, and the Discussion better articulated. The authors might want to consider reducing the Introduction to about one and a half pages, making it more concise.</p></sec><sec id="s2-2"><title>Specific Comments</title><list list-type="order"><list-item><p>The authors should read through the paper to adjust for typographical errors.</p></list-item></list></sec></sec></body><back><fn-group><fn fn-type="conflict"><p>None declared.</p></fn></fn-group><ref-list><title>References</title><ref id="ref1"><label>1</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Majiya</surname><given-names>H</given-names></name><name name-style="western"><surname>Aliyu-Paiko</surname><given-names>M</given-names></name><name name-style="western"><surname>Balogu</surname><given-names>VT</given-names></name><name name-style="western"><surname>Musa</surname><given-names>DA</given-names></name><name name-style="western"><surname>Salihu</surname><given-names>IM</given-names></name><name name-style="western"><surname>Kawu</surname><given-names>AA</given-names></name><etal/></person-group><article-title>Seroprevalence of SARS-CoV-2 in Niger State: pilot cross-sectional study</article-title><source>JMIRx Med</source><year>2023</year><volume>4</volume><fpage>e29587</fpage><pub-id pub-id-type="doi">10.2196/29587</pub-id></nlm-citation></ref></ref-list></back></article>